CompletedPhase 2NCT03717909
Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome
Studying Wolfram syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Birmingham
- Principal Investigator
- Timothy Barrett, PhD, MB, BSUniversity of Birmingham
- Intervention
- Sodium Valproate 200Mg E/C Tablet(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2018 – 2024
Study locations (6)
- CHU de Montpellier, Hopital Gui de Chauliac, Montpellier, France
- Hôpital Européen Georges-Pompidou, Paris, France
- Medical University of Lodz, Lodz, Poland
- Unidad de Gestión Clínica Almería Periferia. Distrito Sanitario Almería, Almería, Spain
- University Hospitals Birmingham, Birmingham, United Kingdom
- Birmingham Women's and Children's Hospital, Birmingham, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03717909 on ClinicalTrials.govOther trials for Wolfram syndrome
Additional recruiting or active studies for the same condition.